Abstract
Background
Locally advanced and metastatic Barrett’s carcinomas account for the majority of this tumor entity at the time of diagnosis. Many studies have shown that a multimodal therapy concept consisting of neoadjuvant chemotherapy followed by resection can result in improved long-term survival in patients responding to chemotherapy. The benefit of a multimodal therapy concept in patients with stage IV disease remains unclear.
Methods
A total of 178 patients with Barrett’s carcinoma who underwent multimodal therapy with resection of the tumor were reviewed. The pathological staging and the clinical course of patients with metastatic disease, who were treated equally, were compared to patients with locally advanced tumors.
Results
As expected, postoperative pathological staging showed that patients with metastatic disease have a more advanced T- and N-status. Moreover, the histopathological response according to Becker showed a chemoresistence in 84% of cases with metastatic disease, whereas 54% of patients with locally advanced carcinomas had a good response rate. Overall survival was poor, with 9 months in the metastatic group.
Conclusions
This is the first study to compare the outcome of a modern multimodal therapy concept in patients with metastatic Barrett’s carcinoma in comparison to patients with the locally advanced form of the disease. There are profound differences in the two groups with regard to survival time and response rates. Because of the poor outcome to date, multimodal therapy with resection of the tumor in stage IV disease cannot be recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Devesa S, Blot W, Fraumeni J (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053
Dolan K, Sutton R, Walker S et al (1999) New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer 80:834–842
Reynolds J, Rahimi P, Hirschl D (2002) Barrett’s esophagus: clinical characteristics. Gastroenterol Clin North Am 31:441–460
Helm J, Enkemann S, Coppola D et al (2005) Dedifferentiation precedes invasion in the progression from Barrett’s metaplasia to esophageal adenocarcinoma. Clin Cancer Res 11:2478–2485
Shaheen N (2005) Advances in Barrett’s esophageal adenocarcinoma. Gastroenterology 128:1554–1566
Fountoulakis A, Zafirellis D, Dolan K et al (2004) Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 91:997–1003
Bonavina L, Via A, Incarbone R et al (2003) Results of surgical therapy in patients with Barrett’s adenocarcinoma. World J Surg 27:1062–1066
DeMeester S (2005) Adenocarcinoma of the esophagus and cardia: a review of disease and its treatment. Ann Surg Oncol 13:12–30
Swisher S, Pisters P, Komaki R et al (2000) Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol 1:387–398
Zacherl J, Sendler A, Stein H et al (2003) Current status of neoadjuvant therapy of adenocarcinoma of the distal esophagus. World J Surg 27:1067–1074
Becker K, Fumagalli U, Mueller J et al (1999) Neoadjuvant chemotherapy for patients with locally advanced gastric carcinoma. Cancer 85:1484–1488
Fink U, Stein H, Siewert J (1998) Multimodal therapy for tumors of the upper gastrointestinal tract. Chirurg 69:349–359
Siewert J, Stein H, Feith M (2003) Surgical approach to invasive adenocarcinoma of the distal esophagus (Barrett’s cancer). World J Surg 27:1058–1061
Feith M, Stein H, Siewert R (2003) Pattern of lymphatic spread of Barrett’s cancer. World J Surg 27:1052–1057
Torres C, Turner J, Wang H et al (1998) Pathologic prognostic factors in Barrett’s-associated adenocarcinoma. Cancer 85:520–528
Peracchia A, Bonavina L, Via A et al (1999) Current trends in the surgical treatment of esophageal and cardia adenocarcinoma. J Exp Clin Cancer Res 18:289–294
Mason G, Micetich K, Aranha G (2001) Long-term survival of a patient with widespread metastases from Barrett’s adenocarcinoma. EJSO 27:509–514
Nakatani K, Tanabe S, Koizumi W et al (2007) Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett’s esophageal cancer. Dis Esophagus 20:173–177
Swanson S, Batirel H, Bueno R et al (2001) Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 72:1918–1924
Becker K, Mueller J, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schauer, M., Stein, H., Lordick, F. et al. Results of a Multimodal Therapy in Patients with Stage IV Barrett’s Adenocarcinoma. World J Surg 32, 2655–2660 (2008). https://doi.org/10.1007/s00268-008-9722-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-008-9722-6